(Q53346102)

13 May 2018

title

Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. (English)

1 reference

13 May 2018

1 reference

Zaucha JM

1

1 reference

13 May 2018

Wyrowinska E

2

1 reference

13 May 2018

Prejzner W

3

1 reference

13 May 2018

Calbecka M

4

1 reference

13 May 2018

Hellmann A

5

1 reference

13 May 2018

publication date

1 June 2006

1 reference

13 May 2018

International Journal of Laboratory Hematology

published in

1 reference

13 May 2018

volume

28

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

208-210

1 reference

13 May 2018

Discontinuation of imatinib therapy after achieving a molecular response

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2257.2006.00772.X

10.1111/J.1365-2257.2006.00772.X

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018